Retatrutide is one of the most-discussed research peptides of recent years. This explainer covers what it is, how it works at the receptor level, and how it differs from the GLP-1 and dual agonists that came before it — all within a research-use context.
Mechanism of action
Retatrutide is a synthetic single-molecule peptide engineered to activate three receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. In research models, simultaneous activation of these three pathways is studied for its combined effects on insulin signalling, glucose handling, lipid metabolism and energy expenditure.
The three receptor targets
- GLP-1 receptor — central to incretin signalling and glucose-dependent insulin release in research models.
- GIP receptor — a second incretin pathway studied alongside GLP-1 for additive metabolic effects.
- Glucagon receptor — adds a distinct axis studied for its influence on energy expenditure and lipid pathways.
How it differs from GLP-1-only and dual agonists
Earlier research peptides act on one or two of these receptors. Semaglutide is a GLP-1 receptor agonist; Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon-receptor activity, making it a triple agonist — sometimes informally called a "GLP-3" compound in research discussion. The practical research interest is whether engaging all three pathways produces a different profile than one or two.
Research findings to date
Retatrutide has been the subject of pre-clinical and early clinical investigation reported in the scientific literature, primarily around metabolic endpoints. As a research compound, the relevant question for laboratory work is reproducible characterisation of its receptor pharmacology — which is why purity and identity verification matter. For the late-stage clinical picture, see our Retatrutide Phase 3 results summary; for the receptor detail, see the mechanism of action explainer.
Research-use framing
Retatrutide supplied by Pepreta is for in-vitro laboratory research only — not for human or animal use. If you are sourcing it for research, see our Retatrutide buying guide and the peptide format overview, and review the batch Certificate of Analysis on the product page.